EMIS Group PLC Trading update and Notice of half year results (7998U)

TIDMEMIS

RNS Number : 7998U

EMIS Group PLC

17 July 2018

17 July 2018

EMIS Group plc

("EMIS Group" or "the Group")

Trading update

Notice of half year results

EMIS Group plc (AIM: EMIS.L), the UK leader in connected healthcare software and services, today announces a trading update for the six months ended 30 June 2018.

Overview

Trading for the half year has been in line with the Board's expectations with revenue ahead of the comparative period as the Group continued to benefit from strong market shares, high levels of recurring revenue and good visibility in its order books and pipelines. The Board's expectations for the full year remain unchanged.

Divisional review

In Primary, Community & Acute Care, the Group's leading primary care market share has been maintained, while constructive discussions with NHS Digital continue with progress made in resolving the service level issues announced in January. The Group advanced again in Community with further contract wins, and the Acute business saw an improved performance.

The roll out of ProScript Connect, the Group's next generation pharmacy dispensary management product in Community Pharmacy, has continued to plan, with the business moving forward positively.

The improvement in trading in Specialist & Care in the second half of 2017 was maintained during the period with a strong focus on operational delivery.

Patient continues to make good progress in building the first UK marketplace for healthcare. A major step in this project was the launch of an upgraded Patient Access app in May. In parallel, patient.info continues to develop its audience with increased focus on advertising sales.

Financial position

The Group's net cash at 30 June 2018 was GBP32.3m (31 December 2017: GBP14.0m), benefiting from the usual seasonal first half inflow.

Notice of half year results

The Group intends to announce its results for the half year ended 30 June 2018 on 31 August 2018.

Andy Thorburn, CEO of EMIS Group, said:

"EMIS Group has continued to trade in line with our expectations, while at the same time we have delivered good progress on the key projects set out in March and on developing our detailed plans for growth. The Board therefore remains confident in the outlook for the business."

For further information, contact:

EMIS Group plc Tel: [phone]

Andy Thorburn, CEO

Peter Southby, CFO

www.emisgroupplc.com

   Numis Securities Limited (Nominated Adviser & Broker)        Tel: [phone] 

Oliver Hardy/Simon Willis/James Black

MHP Communications Tel: [phone]

Reg Hoare/Giles Robinson/Charlie Barker

Information for investors, including analyst consensus forecasts, can be found on the Group's website at www.emisgroupplc.com/investors.

Notes to Editors

EMIS Group is the UK leader in connected healthcare software and services. Its solutions are widely used across every major UK healthcare setting from primary, community & acute care, to high street pharmacies and specialist care services. EMIS Group helps healthcare professionals in over 10,000 organisations share vital information, facilitating better, more efficient healthcare and supporting longer and healthier lives.

EMIS Group serves the following healthcare markets under the EMIS Health brand:

-- Primary, Community & Acute Care, as the UK leader in clinical management systems for healthcare providers and commissioners. EMIS Health products, including the flagship EMIS Web, hold over 40 million patient records and are used by more than 100,000 professionals in nearly 6,000 healthcare organisations.

-- Community Pharmacy, with the UK's single most used integrated community pharmacy and retail system.

   --      Specialist Care, as England's leading provider of diabetic eye screening software and other ophthalmology-related solutions. 

These markets are also supported by other EMIS Group businesses:

-- under the Patient brand, the UK's leading independent provider of patient-centric medical and well-being information and related transactional services.

-- under the Egton brand, providing specialist ICT infrastructure, hardware and engineering services, and non-clinical software into health and social care.

-- under the EMIS Care brand, providing healthcare screening programmes such as diabetic eye screening.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

TSTRFMFTMBMBBMP

(END) Dow Jones Newswires

July 17, 2018 02:00 ET (06:00 GMT)